Daejeon, South Korea

Beomseok Seo

USPTO Granted Patents = 6 

Average Co-Inventor Count = 15.4

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2021-2025

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Beomseok Seo: Innovator in Antibody-Drug Conjugates

Introduction

Beomseok Seo is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of biochemistry, particularly in the development of antibody-drug conjugates. With a total of 6 patents to his name, Seo's work is paving the way for advancements in therapeutic applications.

Latest Patents

Seo's latest patents include innovative compounds and compositions that utilize substituted benzodiazepines as antibody-drug conjugates. One of his notable disclosures provides details on these compounds, which are designed to enhance the efficacy of therapeutic agents. Another significant patent focuses on antibody-drug conjugates that incorporate anti-B7-H3 antibodies. This patent outlines methods for linking active agents to the antibody through a specialized linker, which may improve the targeting and effectiveness of treatments for various diseases.

Career Highlights

Throughout his career, Beomseok Seo has worked with several companies, including Intocell, Inc. and Y-Biologics Inc. His experience in these organizations has allowed him to collaborate with other experts in the field and contribute to groundbreaking research and development.

Collaborations

Seo has collaborated with notable colleagues such as Taekyo Park and Sung Ho Woo. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Beomseok Seo's contributions to the field of antibody-drug conjugates demonstrate his commitment to advancing medical science. His innovative patents and collaborations highlight his role as a key figure in biochemistry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…